The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study
暂无分享,去创建一个
M. J. van den Bent | O. Schijns | M. Smits | A. Postma | M. Broen | M. Wijnenga | H. Dubbink | M. Anten | J. Beckervordersandforth | M. Broen | M. P. Broen
[1] Armin Giese,et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma , 2018, Neuro-oncology.
[2] M. J. van den Bent,et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.
[3] Karra A. Jones,et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status , 2017, Journal of Neuro-Oncology.
[4] W. Dinjens,et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.
[5] Sohil H. Patel,et al. T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project , 2017, Clinical Cancer Research.
[6] M. J. van den Bent,et al. Imaging Correlates of Adult Glioma Genotypes. , 2017, Radiology.
[7] Susan M. Chang,et al. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics , 2017, Neuro-oncology.
[8] M. J. van den Bent,et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective , 2017, Journal of Neuro-Oncology.
[9] Susan M. Chang,et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide , 2016, Neuro-oncology.
[10] M. J. van den Bent,et al. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. , 2016, The Journal of molecular diagnostics : JMD.
[11] T. Tominaga,et al. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.
[12] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[13] Pieter Wesseling,et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.
[14] Andrei I Holodny,et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.
[15] S. Heiland,et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.
[16] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[17] Gabriele Schackert,et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.
[18] S. Plevritis,et al. Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.
[19] Neema Jamshidi,et al. Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. , 2013, Radiology.
[20] G. Reifenberger,et al. Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.
[21] Geirmund Unsgård,et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.
[22] B. Tress,et al. MR imaging characteristics of protoplasmic astrocytomas , 2011, Neuroradiology.
[23] R Grant,et al. Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force , 2010, European journal of neurology.
[24] Luc Taillandier,et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. , 2009, Neuro-oncology.
[25] K. Hoang-Xuan,et al. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas , 2008, Neuropathology : official journal of the Japanese Society of Neuropathology.
[26] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[27] K. Aldape,et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.
[28] J. Rutka,et al. Fluid-attenuated Inversion Recovery Ring Sign as a Marker of Dysembryoplastic Neuroepithelial Tumors , 2007, Journal of computer assisted tomography.
[29] Olivier Delattre,et al. Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.
[30] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.